ArticleHematological oncology2025

Management of Adverse Reactions to Loncastuximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Narendranath Epperla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.